One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Two Biologic-Assignment Studies Evaluating the Efficacy of Hematopoietic Cell Transplant Among Older Patients With High-Risk Myelodysplastic Syndrome.
Gooley, Ted A. PhD 1,,
doi : 10.1200/JCO.21.01594
Volume 39(30) pgs. 3311-3414 October 20, 2021
Is the United States Ready for Regionalized Cancer Care?.
Court, Colin M. MD, PHD 1; Strong, Vivian E. MD 1,
doi : 10.1200/JCO.21.01692
Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).
Kroger, Nicolaus MD 1,,; Sockel, Katja MD 2,; Wolschke, Christine MD 1; Bethge, Wolfgang MD 3,; Schlenk, Richard F. MD 4,5,; Wolf, Dominik MD 6,7,8; Stadler, Michael MD 9; Kobbe, Guido MD 10,; Wulf, Gerald MD 11,; Bug, Gesine MD 12,; Schafer-Eckart, Kerstin MD 13; Scheid, Christof MD 14,; Nolte, Florian MD 15; Kronke, Jan MD 16,; Stelljes, Matthias MD 17,; Beelen, Dietrich MD 18,; Heinzelmann, Marion 1; Haase, Detlef MD 11,; Buchner, Hannes PhD 19,; Bleckert, Gabriele PhD 19; Giagounidis, Aristoteles MD 20,; Platzbecker, Uwe MD 2,21,
doi : 10.1200/JCO.20.02724
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
Nakamura, Ryotaro MD 1,; Saber, Wael MD, MS 2; Martens, Michael J. PhD 2; Ramirez, Alyssa BS 3; Scott, Bart MD 4,; Oran, Betul MD 5,; Leifer, Eric PhD 6; Tamari, Roni MD 7; Mishra, Asmita MD 8,; Maziarz, Richard T. MD 9,; McGuirk, Joseph DO 10,; Westervelt, Peter MD, PhD 11,; Vasu, Sumithira MBBS 12,; Patnaik, Mrinal MBBS 13,; Kamble, Rammurti MD 14; Forman, Stephen J. MD 1,; Sekeres, Mikkael A. MD, MS 15,; Appelbaum, Frederick MD 4,; Mendizabal, Adam PhD 3; Logan, Brent PhD 2,; Horowitz, Mary MD, MS 2,; Cutler, Corey MD, MPH 16,,
doi : 10.1200/JCO.20.03380
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan, Jing MD 1,; Tan, Yue BS 2; Wang, Guoling BS 2; Deng, Biping MS 3; Ling, Zhuojun MD 4; Song, Weiliang MD 4; Seery, Samuel PhD 5,6; Zhang, Yanlei MS 7,; Peng, Shuixiu MS 7,; Xu, Jinlong MD 4; Duan, Jiajia MD 4; Wang, Zelin MD 4; Yu, Xinjian MD 8; Zheng, Qinlong MD 8; Xu, Xiuwen MD 8; Yuan, Ying PhD 9,; Yan, Fangrong PhD 10; Tian, Zhenglong PhD 11; Tang, Kaiting BS 4; Zhang, Jiecheng BS 12; Chang, Alex H. PhD 7,13,; Feng, Xiaoming PhD 2,14,
doi : 10.1200/JCO.21.00389
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia.
Roddie, Claire MD, PhD 1,2,; Dias, Juliana PhD 1,3; O'Reilly, Maeve A. MD 2,; Abbasian, Mahnaz MSc 1; Cadinanos-Garai, Amaia MSc 1; Vispute, Ketki PhD 1,; Bosshard-Carter, Leticia MSc 1; Mitsikakou, Marina MSc 1; Mehra, Vedika MSc 1; Roddy, Harriet MSc 1; Hartley, John A. PhD 1,4,; Spanswick, Victoria PhD 1,4; Lowe, Helen PhD 1,4; Popova, Bilyana MSc 5; Clifton-Hadley, Laura PhD 5,; Wheeler, Graham PhD 5,6,; Olejnik, Joanna MSc 5; Bloor, Adrian MD, PhD 7,; Irvine, David MD, PhD 8,; Wood, Leigh MSc 2,; Marzolini, Maria A. V. MD, PhD 2; Domning, Sabine PhD 9; Farzaneh, Farzin PhD 9,; Lowdell, Mark W. PhD 1,3,; Linch, David C. MD 1,; Pule, Martin A. MD, PhD 1,10,,; Peggs, Karl S. MD 1,2,
doi : 10.1200/JCO.21.00917
Clinical Outcomes Following Regionalization of Gastric Cancer Care in a US Integrated Health Care System.
Teh, Swee H. MD 1,; Uong, Stephen MPH 2,; Lin, Teresa Y. MPH 2; Shiraga, Sharon MD 1,; Li, Yan MD 3; Gong, I-Yeh MD 3; Herrinton, Lisa J. PhD 2; Li, Robert A. MD 1
doi : 10.1200/JCO.21.00480
Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).
Bellini, Angela PhD 1,2,3; Potschger, Ulrike PhD 4,5; Bernard, Virginie PhD 6; Lapouble, Eve PhD 7; Baulande, Sylvain PhD 6; Ambros, Peter F. PhD 5; Auger, Nathalie PhD 8; Beiske, Klaus MD, PhD 9; Bernkopf, Marie PhD 5; Betts, David R. PhD 10; Bhalshankar, Jaydutt MSc 1,2,3; Bown, Nick PhD 11; de Preter, Katleen PhD 12; Clement, Nathalie PhD 1,2,3; Combaret, Valerie PhD 13; Font de Mora, Jaime PhD 14; George, Sally L. MD, PhD 15; Jimenez, Irene MD 1,2,3; Jeison, Marta PhD 16; Marques, Barbara PhD 17; Martinsson, Tommy PhD 18; Mazzocco, Katia PhD 19; Morini, Martina PhD 20; Muhlethaler-Mottet, Annick PhD 21; Noguera, Rosa MD 22; Pierron, Gaelle PhD 7; Rossing, Maria PhD 23; Taschner-Mandl, Sabine PhD 5; Van Roy, Nadine PhD 12; Vicha, Ales PhD 24; Chesler, Louis MD, PhD 25; Balwierz, Walentyna MD 26,; Castel, Victoria MD, PhD 27; Elliott, Martin MD 28,; Kogner, Per MD, PhD 29; Laureys, Genevieve MD, PhD 30; Luksch, Roberto MD 31; Malis, Josef MD 24; Popovic-Beck, Maja MD 32; Ash, Shifra MD 33; Delattre, Olivier MD 2,3,6; Valteau-Couanet, Dominique MD, PhD 34,; Tweddle, Deborah A. MD, PhD 35,; Ladenstein, Ruth MD, PhD 36,37,; Schleiermacher, Gudrun MD, PhD 1,2,3,,
doi : 10.1200/JCO.21.00086
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park, Keunchil MD, PhD 1,; Haura, Eric B. MD 2,; Leighl, Natasha B. MD 3,; Mitchell, Paul MD 4,; Shu, Catherine A. MD 5,; Girard, Nicolas MD, PhD 6,; Viteri, Santiago MD 7,; Han, Ji-Youn MD, PhD 8,; Kim, Sang-We MD, PhD 9; Lee, Chee Khoon MD 10,; Sabari, Joshua K. MD 11,; Spira, Alexander I. MD, PhD 12,; Yang, Tsung-Ying MD, PhD 13; Kim, Dong-Wan MD, PhD 14,; Lee, Ki Hyeong MD, PhD 15,; Sanborn, Rachel E. MD 16,; Trigo, Jose MD 17,; Goto, Koichi MD, PhD 18,; Lee, Jong-Seok MD, PhD 19; Yang, James Chih-Hsin MD, PhD 20,; Govindan, Ramaswamy MD 21,; Bauml, Joshua M. MD 22,; Garrido, Pilar MD, PhD 23,; Krebs, Matthew G. MD, PhD 24,; Reckamp, Karen L. MD 25,; Xie, John PhD 26,; Curtin, Joshua C. PhD 26,; Haddish-Berhane, Nahor PhD 26,; Roshak, Amy BS 26,; Millington, Dawn MS 26,; Lorenzini, Patricia MS 26,; Thayu, Meena MD 26,; Knoblauch, Roland E. MD, PhD 26,; Cho, Byoung Chul MD, PhD 27,,
doi : 10.1200/JCO.21.00662
Amivantamab: Treating EGFR Exon 20-Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation.
Kohler, Jens MD 1,; Janne, Pasi A. MD, PhD 1,2,3,,
doi : 10.1200/JCO.21.01494
The 5-Year Paradigm in DCIS of the Breast: Unexpected Lessons From the NSABP B-43 Trial.
Van Bockstal, Mieke R. MD, PhD; Libbrecht, Louis MD, PhD; Galant, Christine MD, PhD
doi : 10.1200/JCO.21.00968
Reply to M. R. Van Bockstal et al.
Cobleigh, Melody A. MD; Anderson, Stewart J. PhD
doi : 10.1200/JCO.21.01587
Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma.
Powles, Thomas MD; Petrylak, Daniel P. MD; Rosenberg, Jonathan E. MD
doi : 10.1200/JCO.21.01430
Reply to T. Powles et al.
Tagawa, Scott T. MD, MS; Grivas, Petros MD, PhD
doi : 10.1200/JCO.21.01673
Caregiver Exclusion in Fighting Cancer During COVID-19: Splitting the Risk, Doubling the Team.
Moroni, Matteo PhD; Bruera, Eduardo PhD
doi : 10.1200/JCO.21.00945
